Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study

American Journal of Psychiatry

Volumn 175, Issue 7, 2018, Pages 620-630

  Canuso, Carla M ^a   Singh, Jaskaran B ^a   Fedgchin, Maggie ^a   Alphs, Larry ^a   Lane, Rosanne ^a   Lim, Pilar ^a   Pinter, Christine ^a   Hough, David ^a   Sanacora, Gerard ^a   Manji, Husseini ^a   Drevets, Wayne C ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESKETAMINE; PLACEBO; SERTRALINE; KETAMINE;

ADULT; AGGRESSION; AGITATION; ANXIETY; ARTICLE; CONTROLLED STUDY; DISSOCIATIVE DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; EFFECT SIZE; EUPHORIA; FEMALE; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PANIC; POPULATION RESEARCH; PRIORITY JOURNAL; PROOF OF CONCEPT; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE IDEATION AND BEHAVIOR ASSESSMENT TOOL; TASTE DISORDER; TREATMENT OUTCOME; VERTIGO; VOMITING; CLINICAL TRIAL; INTRANASAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; RISK FACTOR; SUICIDE;

ADMINISTRATION, INTRANASAL; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETAMINE; MALE; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SUICIDE;

EID: 85049253714     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2018.17060720     Document Type: Article

References (39)

1. World Health Organization (WHO): Preventing Suicide: A Global Imperative. Geneva, WHO, 2014. http://www.who.int/mental-health/suicide-prevention/world-report-2014/en/
2. National Institute of Mental Health: Major Depression Among Adults. https://www.nimh.nih.gov/health/statistics/prevalence/majordepression-among-adults.shtml
3. Cavanagh JT, Carson AJ, Sharpe M, et al: Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003; 33:395-405
4. Holma KM, Melartin TK, Haukka J, et al: Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a fiveyear prospective study. Am J Psychiatry 2010; 167:801-808
5. Centers for Disease Control and Prevention: Web-Based Injury Statistics Query and Reporting System (WISQARS). Atlanta, National Center for Injury Prevention and Control. http://www.cdc.gov/injury/wisqars/leading-causes-death.html
6. Centers for Disease Control and Prevention: Suicide: Consequences. http://www.cdc.gov/ViolencePrevention/suicide/consequences.html
7. Bickley H, Hunt IM, Windfuhr K, et al: Suicide within two weeks of discharge from psychiatric inpatient care: a case-control study. Psychiatr Serv 2013; 64:653-659
8. McAuliffe CM: Suicidal ideation as an articulation of intent: a focus for suicide prevention? Arch Suicide Res 2002; 6:325-338
9. Deisenhammer EA, Ing CM, Strauss R, et al: The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry 2009; 70:19-24
10. Montgomery SA, Dunner DL, Dunbar GC: Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995; 5:5-13
11. van der Feltz-Cornelis CM, Sarchiapone M, Postuvan V, et al: Best practice elements of multilevel suicide prevention strategies: a review of systematic reviews. Crisis 2011; 32:319-333
12. Wasserman D, Rihmer Z, Rujescu D, et al: The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 2012; 27:129-141
13. Duman RS, Aghajanian GK, Sanacora G, et al: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22:238-249
14. Aanhet Rot M, Collins KA, Murrough JW, et al: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67:139-145
15. Berman RM, Cappiello A, Anand A, et al: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47:351-354
16. Ibrahim L, Diazgranados N, Franco-Chaves J, et al: Course of improvement in depressive symptoms to a single intravenous infusion of ketaminevsadd-onriluzole: results froma4-week, double-blind, placebocontrolled study. Neuropsychopharmacology 2012; 37:1526-1533
17. Mathew SJ, Murrough JW, Aanhet Rot M, et al: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010; 13:71-82
18. Murrough JW, Iosifescu DV, Chang LC, et al: Antidepressant efficacy of ketamine in treatment-resistantmajor depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170:1134-1142
19. Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-864
20. Diaz Granados N, Ibrahim LA, Brutsche NE, et al: Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71:1605-1611
21. Ionescu DF, Swee MB, Pavone KJ, et al: Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 2016; 77:e719-e725
22. Price RB, Nock MK, Charney DS, et al: Effectsof intravenousketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66:522-526
23. Ballard ED, Ionescu DF, Vande Voort JL, et al: Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 2014; 58:161-166
24. Ballard ED, Luckenbaugh DA, Richards EM, et al: Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res 2015; 68:68-73
25. Wilkinson ST, Ballard ED, Bloch MH, et al: The effect of a single dose of intravenous ketamineon suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 2018; 175: 150-158
26. Grunebaum MF, Galfalvy HC, Choo TH, et al: Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolamcontrolled randomized clinical trial. Am J Psychiatry (Epub ahead of print, Dec 5, 2017)
27. Covvey JR, Crawford AN, Lowe DK: Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother 2012; 46:117-123
28. Singh JB, Fedgchin M, Daly E, et al: Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 2016; 80:424-431
29. Daly EJ, Singh JB, Fedgchin M, et al: Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatmentresistant depression: a randomized clinical trial. JAMA 2018; 75: 139-148
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision (DSM-IV-TR). Washington, DC, American Psychiatric Association, 2000
31. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
32. Diazgranados N, Ibrahim L, Brutsche NE, et al: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatmentresistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802
33. Zarate CA Jr, Brutsche NE, Ibrahim L, et al: Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71:939-946
34. Alphs L, Canuso C, Williamson D, et al: Evaluating changes in factors associated with suicidal thinking using the Suicide Ideation and Behavior Assessment Tool (SIBAT). Neuropsychopharmacology 2016; 41(suppl 1S):S189
35. Bremner JD, Krystal JH, Putnam FW, et al: Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11:125-136
36. Murrough JW, Soleimani L, DeWilde KE, et al: Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015; 45:3571-3580
37. Liu Y, Lin D, Wu B, et al: Ketamine abuse potential and use disorder. Brain Res Bull 2016; 126:68-73
38. Brady KT, Balster RL: Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. Pharmacol Biochem Behav 1982; 17:291-295
39. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs: Ketamine use: a review. Addiction 2012; 107:27-38